For the year ending 2025-12-31, AARD had -$14,590K decrease in cash & cash equivalents over the period. -$54,267K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -57,591 |
| Credit loss - related party accounts receivable | 0 |
| Stock-based compensation expense | 3,948 |
| Non-cash lease expense | 380 |
| Unrealized loss on short-term investments | -5 |
| Amortization of discount on short-term investments | 1,306 |
| Depreciation expense | 36 |
| Prepaid expenses and other assets | 5,960 |
| Accounts payable | 239 |
| Accrued liabilities | 6,415 |
| Operating lease liability | -338 |
| Net cash used in operating activities | -54,172 |
| Purchases of short-term investments | 129,599 |
| Maturities/sales of short-term investments | 80,027 |
| Purchases of property and equipment | 95 |
| Net cash used in investing activities | -49,667 |
| Proceeds from sale and issuance of common stock in initial public offering, net of underwriting discounts | 91,075 |
| Financing costs paid in connection with initial public offering | 2,387 |
| Proceeds from sale and issuance of series c convertible preferred stock | 0 |
| Financing costs paid in connection with issuance of series c convertible preferred stock | 0 |
| Proceeds from exercises of common stock options | 366 |
| Proceeds from issuance of common stock under employee stock purchase plan | 195 |
| Costs paid in connection with deferred financing costs | 0 |
| Net cash provided by financing activities | 89,249 |
| Net (decrease) increase in cash and cash equivalents | -14,590 |
| Cash and cash equivalents at beginning of year | 61,641 |
| Cash and cash equivalents at end of year | 47,051 |
Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc. (AARD)